PLUS THERAPEUTICS Inc

Financials

Flusso di cassa derivante dalle attività operative -1.21 M-6.17 M-5.8 M-2.55 M-6.26 M -20.77 M Flussi di cassa derivanti dalle attività di investimento 64 K3.56 M-4.63 M1.3 M-1.08 M -854 K Liquidità derivante dalle attività di finanziamento 012.4 M2.8 M12.31 M2.8 M 30.31 M Liquidità libera -1.22 M-6.17 M-5.8 M-2.58 M-6.29 M -20.84 M

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company headquartered in Houston, Texas, that develops targeted radiotherapeutics and diagnostic services for brain and central nervous system cancers. The company’s lead therapeutic candidate, marketed as REYOBIQ™, is an investigational liposomal radiopharmaceutical under clinical evaluation for recurrent glioblastoma, leptomeningeal metastases, and certain pediatric brain cancers. Plus Therapeutics also commercialized a molecular diagnostic service, CNSide®.

PSTV

Financials

PLUS THERAPEUTICS Inc

Notizie

Plus Therapeutics nomina Eric J. Daniels Chief Development Officer

Plus Therapeutics nomina Eric Daniels chief development officer

Le azioni Plus Therapeutics salgono dopo il riconoscimento FDA di farmaco orfano

La FDA concede lo status di farmaco orfano a REYOBIQ di Plus Therapeutics

CNSide Diagnostics ottiene copertura da Highmark per test CSF

D. Boral Capital declassa il rating di Plus Therapeutics per il reverse split

Plus Therapeutics approva un raggruppamento azionario di 1 a 25

Plus Therapeutics nomina Ronald A. Andrews nel consiglio dopo dimissioni di un direttore

Plus Therapeutics nomina Ron Andrews nel consiglio di amministrazione

Plus Therapeutics (PSTV) Reports Break-Even Earnings for Q4

Nektar Therapeutics (NKTR) Reports Q4 Loss, Tops Revenue Estimates

Guardian Pharmacy Services (GRDN) Surpasses Q4 Earnings and Revenue Estimates